NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors
Christoph Schulz, Volker Heinemann(LMU Klinikum), Thomas Kubin(Kreisklinik Trostberg), Sebastian Stintzing(Humboldt-Universität zu Berlin), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Dominik Paul Modest(Berliner Hochschule für Technik), Michael Geißler(Klinikum Esslingen), Heribert Stauder(Krankenhaus Barmherzige Brüder), Volker Kunzmann(University of Würzburg), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Clemens Gießen, Karsten Ridwelski(University Hospital Magdeburg), Axel Wein(Friedrich-Alexander-Universität Erlangen-Nürnberg), Martin Fuchs(München Klinik Bogenhausen), Frank Kullmann(Klinikum Weiden), Claus Schäfer(Bionorica (Germany))
Cited by 126
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k